Cagrilintide clinical trials

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

This study, called REDEFINE 3, investigates a new medicine, CagriSema, for people with heart and blood vessel diseases. It aims to see if CagriSema can reduce the risk of serious events like heart attacks and strokes.

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

This study looks at how a new medicine called CagriSema helps people who are overweight lose weight. It compares CagriSema to other medicines and a dummy medicine. Participants will take a weekly injection, and the study will last about 3 and a half years.

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

This study looks at a new medicine called cagrilintide for people with overweight or obesity and type 2 diabetes. It aims to see how well cagrilintide helps people lose weight. Participants will receive either the new medicine or a dummy medicine.

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

This study investigates if combining two hormones, GIP and Amylin, given weekly by injection, can reduce stomach side effects in adults who are overweight or obese. It's comparing a new combination to one of the hormones alone.

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

This study is testing a new medicine called Cagrilintide to see if it helps people living with overweight or obesity to lose weight. Some people will get the new medicine, and others will get a dummy treatment. The study will last about 18 months for each person.

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

This study is looking at a new medicine called CagriSema to help people with obesity lose weight. It compares CagriSema to a dummy medicine over three years. Participants won't know if they're getting the active medicine or the dummy medicine. The aim is to see how well it works long-term.

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

This study looks at new treatments, CagriSema and cagrilintide, for children and teenagers aged 8-18 who are overweight. It compares these new drugs to an existing medicine (semaglutide) or a dummy drug (placebo) to see how well they help with weight loss.

Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity

This study is looking into new ways to help children and teenagers manage their weight. It's testing a medicine called cagrilintide, both by itself and with another medicine called semaglutide, to see how well they work and if they are safe for weight loss.

Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor

Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4 mg/2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people with chronic kidney disease and type 2 diabetes living with overweight or obesity.

Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease